Antiviral neutralizing antibody to Hantaan virus as determined by plaque reduction technique
Summary The 76–118 strain of Hantaan virus was titrated in E6 (Vero) cells by the plaque method using agarose overlay medium. Visible plaques, formed 10 days post-infection, were uniformly 2–3 mm in diameter. Dose-response experiments showed that a single infectious particle initiated the formation...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
1985 |
|---|
| Umfang: |
10 |
|---|
| Reproduktion: |
Springer Online Journal Archives 1860-2002 |
|---|---|
| Übergeordnetes Werk: |
in: Archives of virology - 1939, 84(1985) vom: März/Apr., Seite 197-206 |
| Übergeordnetes Werk: |
volume:84 ; year:1985 ; month:03/04 ; pages:197-206 ; extent:10 |
| Links: |
|---|
| Katalog-ID: |
NLEJ208275169 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLEJ208275169 | ||
| 003 | DE-627 | ||
| 005 | 20230506160955.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 070528s1985 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)NLEJ208275169 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 245 | 1 | 0 | |a Antiviral neutralizing antibody to Hantaan virus as determined by plaque reduction technique |
| 264 | 1 | |c 1985 | |
| 300 | |a 10 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Summary The 76–118 strain of Hantaan virus was titrated in E6 (Vero) cells by the plaque method using agarose overlay medium. Visible plaques, formed 10 days post-infection, were uniformly 2–3 mm in diameter. Dose-response experiments showed that a single infectious particle initiated the formation of a plaque. Infectivity titers by the plaque method were equivalent to those obtained by the endpoint method (TCID50) using the immunofluorescence antibody technique (IFA) for antigen detection. The single-cycle growth pattern of the virus showed an eclipse phase of 7 to 9 hours, with production of cell-free infectious virus 18 hours post-infection. Plaque reduction neutralization tests suggested that complement enhanced the neutralizing activity of sera; rat sera were particularly complement-dependent. The plaque reduction neutralization test was about 10 times more sensitive than the TCID50 neutralization test. Convalescent phase sera from patients with hemorrhagic fever with renal syndrome (HFRS) having higher IF antibody titers to Hantaan virus than to nephropathia epidemica (NE) virus were capable of neutralizing Hantaan virus, while sera from patients with higher IF antibody titers to NE virus than Hantaan virus did not contain neutralizing antibody to Hantaan virus. | ||
| 533 | |f Springer Online Journal Archives 1860-2002 | ||
| 700 | 1 | |a Takenaka, A. |4 oth | |
| 700 | 1 | |a Gibbs, C. J. |4 oth | |
| 700 | 1 | |a Gajdusek, D. C. |4 oth | |
| 773 | 0 | 8 | |i in |t Archives of virology |d 1939 |g 84(1985) vom: März/Apr., Seite 197-206 |w (DE-627)NLEJ18899582X |w (DE-600)1458460-8 |x 1432-8798 |7 nnns |
| 773 | 1 | 8 | |g volume:84 |g year:1985 |g month:03/04 |g pages:197-206 |g extent:10 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/BF01378972 |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a ZDB-1-SOJ | ||
| 912 | |a GBV_NL_ARTICLE | ||
| 951 | |a AR | ||
| 952 | |d 84 |j 1985 |c 3/4 |h 197-206 |g 10 | ||
| matchkey_str |
article:14328798:1985----::niianurlznatbdthnaniuadtriebpa |
|---|---|
| hierarchy_sort_str |
1985 |
| publishDate |
1985 |
| allfields |
(DE-627)NLEJ208275169 DE-627 ger DE-627 rakwb eng Antiviral neutralizing antibody to Hantaan virus as determined by plaque reduction technique 1985 10 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Summary The 76–118 strain of Hantaan virus was titrated in E6 (Vero) cells by the plaque method using agarose overlay medium. Visible plaques, formed 10 days post-infection, were uniformly 2–3 mm in diameter. Dose-response experiments showed that a single infectious particle initiated the formation of a plaque. Infectivity titers by the plaque method were equivalent to those obtained by the endpoint method (TCID50) using the immunofluorescence antibody technique (IFA) for antigen detection. The single-cycle growth pattern of the virus showed an eclipse phase of 7 to 9 hours, with production of cell-free infectious virus 18 hours post-infection. Plaque reduction neutralization tests suggested that complement enhanced the neutralizing activity of sera; rat sera were particularly complement-dependent. The plaque reduction neutralization test was about 10 times more sensitive than the TCID50 neutralization test. Convalescent phase sera from patients with hemorrhagic fever with renal syndrome (HFRS) having higher IF antibody titers to Hantaan virus than to nephropathia epidemica (NE) virus were capable of neutralizing Hantaan virus, while sera from patients with higher IF antibody titers to NE virus than Hantaan virus did not contain neutralizing antibody to Hantaan virus. Springer Online Journal Archives 1860-2002 Takenaka, A. oth Gibbs, C. J. oth Gajdusek, D. C. oth in Archives of virology 1939 84(1985) vom: März/Apr., Seite 197-206 (DE-627)NLEJ18899582X (DE-600)1458460-8 1432-8798 nnns volume:84 year:1985 month:03/04 pages:197-206 extent:10 http://dx.doi.org/10.1007/BF01378972 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 84 1985 3/4 197-206 10 |
| spelling |
(DE-627)NLEJ208275169 DE-627 ger DE-627 rakwb eng Antiviral neutralizing antibody to Hantaan virus as determined by plaque reduction technique 1985 10 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Summary The 76–118 strain of Hantaan virus was titrated in E6 (Vero) cells by the plaque method using agarose overlay medium. Visible plaques, formed 10 days post-infection, were uniformly 2–3 mm in diameter. Dose-response experiments showed that a single infectious particle initiated the formation of a plaque. Infectivity titers by the plaque method were equivalent to those obtained by the endpoint method (TCID50) using the immunofluorescence antibody technique (IFA) for antigen detection. The single-cycle growth pattern of the virus showed an eclipse phase of 7 to 9 hours, with production of cell-free infectious virus 18 hours post-infection. Plaque reduction neutralization tests suggested that complement enhanced the neutralizing activity of sera; rat sera were particularly complement-dependent. The plaque reduction neutralization test was about 10 times more sensitive than the TCID50 neutralization test. Convalescent phase sera from patients with hemorrhagic fever with renal syndrome (HFRS) having higher IF antibody titers to Hantaan virus than to nephropathia epidemica (NE) virus were capable of neutralizing Hantaan virus, while sera from patients with higher IF antibody titers to NE virus than Hantaan virus did not contain neutralizing antibody to Hantaan virus. Springer Online Journal Archives 1860-2002 Takenaka, A. oth Gibbs, C. J. oth Gajdusek, D. C. oth in Archives of virology 1939 84(1985) vom: März/Apr., Seite 197-206 (DE-627)NLEJ18899582X (DE-600)1458460-8 1432-8798 nnns volume:84 year:1985 month:03/04 pages:197-206 extent:10 http://dx.doi.org/10.1007/BF01378972 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 84 1985 3/4 197-206 10 |
| allfields_unstemmed |
(DE-627)NLEJ208275169 DE-627 ger DE-627 rakwb eng Antiviral neutralizing antibody to Hantaan virus as determined by plaque reduction technique 1985 10 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Summary The 76–118 strain of Hantaan virus was titrated in E6 (Vero) cells by the plaque method using agarose overlay medium. Visible plaques, formed 10 days post-infection, were uniformly 2–3 mm in diameter. Dose-response experiments showed that a single infectious particle initiated the formation of a plaque. Infectivity titers by the plaque method were equivalent to those obtained by the endpoint method (TCID50) using the immunofluorescence antibody technique (IFA) for antigen detection. The single-cycle growth pattern of the virus showed an eclipse phase of 7 to 9 hours, with production of cell-free infectious virus 18 hours post-infection. Plaque reduction neutralization tests suggested that complement enhanced the neutralizing activity of sera; rat sera were particularly complement-dependent. The plaque reduction neutralization test was about 10 times more sensitive than the TCID50 neutralization test. Convalescent phase sera from patients with hemorrhagic fever with renal syndrome (HFRS) having higher IF antibody titers to Hantaan virus than to nephropathia epidemica (NE) virus were capable of neutralizing Hantaan virus, while sera from patients with higher IF antibody titers to NE virus than Hantaan virus did not contain neutralizing antibody to Hantaan virus. Springer Online Journal Archives 1860-2002 Takenaka, A. oth Gibbs, C. J. oth Gajdusek, D. C. oth in Archives of virology 1939 84(1985) vom: März/Apr., Seite 197-206 (DE-627)NLEJ18899582X (DE-600)1458460-8 1432-8798 nnns volume:84 year:1985 month:03/04 pages:197-206 extent:10 http://dx.doi.org/10.1007/BF01378972 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 84 1985 3/4 197-206 10 |
| allfieldsGer |
(DE-627)NLEJ208275169 DE-627 ger DE-627 rakwb eng Antiviral neutralizing antibody to Hantaan virus as determined by plaque reduction technique 1985 10 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Summary The 76–118 strain of Hantaan virus was titrated in E6 (Vero) cells by the plaque method using agarose overlay medium. Visible plaques, formed 10 days post-infection, were uniformly 2–3 mm in diameter. Dose-response experiments showed that a single infectious particle initiated the formation of a plaque. Infectivity titers by the plaque method were equivalent to those obtained by the endpoint method (TCID50) using the immunofluorescence antibody technique (IFA) for antigen detection. The single-cycle growth pattern of the virus showed an eclipse phase of 7 to 9 hours, with production of cell-free infectious virus 18 hours post-infection. Plaque reduction neutralization tests suggested that complement enhanced the neutralizing activity of sera; rat sera were particularly complement-dependent. The plaque reduction neutralization test was about 10 times more sensitive than the TCID50 neutralization test. Convalescent phase sera from patients with hemorrhagic fever with renal syndrome (HFRS) having higher IF antibody titers to Hantaan virus than to nephropathia epidemica (NE) virus were capable of neutralizing Hantaan virus, while sera from patients with higher IF antibody titers to NE virus than Hantaan virus did not contain neutralizing antibody to Hantaan virus. Springer Online Journal Archives 1860-2002 Takenaka, A. oth Gibbs, C. J. oth Gajdusek, D. C. oth in Archives of virology 1939 84(1985) vom: März/Apr., Seite 197-206 (DE-627)NLEJ18899582X (DE-600)1458460-8 1432-8798 nnns volume:84 year:1985 month:03/04 pages:197-206 extent:10 http://dx.doi.org/10.1007/BF01378972 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 84 1985 3/4 197-206 10 |
| allfieldsSound |
(DE-627)NLEJ208275169 DE-627 ger DE-627 rakwb eng Antiviral neutralizing antibody to Hantaan virus as determined by plaque reduction technique 1985 10 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Summary The 76–118 strain of Hantaan virus was titrated in E6 (Vero) cells by the plaque method using agarose overlay medium. Visible plaques, formed 10 days post-infection, were uniformly 2–3 mm in diameter. Dose-response experiments showed that a single infectious particle initiated the formation of a plaque. Infectivity titers by the plaque method were equivalent to those obtained by the endpoint method (TCID50) using the immunofluorescence antibody technique (IFA) for antigen detection. The single-cycle growth pattern of the virus showed an eclipse phase of 7 to 9 hours, with production of cell-free infectious virus 18 hours post-infection. Plaque reduction neutralization tests suggested that complement enhanced the neutralizing activity of sera; rat sera were particularly complement-dependent. The plaque reduction neutralization test was about 10 times more sensitive than the TCID50 neutralization test. Convalescent phase sera from patients with hemorrhagic fever with renal syndrome (HFRS) having higher IF antibody titers to Hantaan virus than to nephropathia epidemica (NE) virus were capable of neutralizing Hantaan virus, while sera from patients with higher IF antibody titers to NE virus than Hantaan virus did not contain neutralizing antibody to Hantaan virus. Springer Online Journal Archives 1860-2002 Takenaka, A. oth Gibbs, C. J. oth Gajdusek, D. C. oth in Archives of virology 1939 84(1985) vom: März/Apr., Seite 197-206 (DE-627)NLEJ18899582X (DE-600)1458460-8 1432-8798 nnns volume:84 year:1985 month:03/04 pages:197-206 extent:10 http://dx.doi.org/10.1007/BF01378972 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 84 1985 3/4 197-206 10 |
| language |
English |
| source |
in Archives of virology 84(1985) vom: März/Apr., Seite 197-206 volume:84 year:1985 month:03/04 pages:197-206 extent:10 |
| sourceStr |
in Archives of virology 84(1985) vom: März/Apr., Seite 197-206 volume:84 year:1985 month:03/04 pages:197-206 extent:10 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| isfreeaccess_bool |
false |
| container_title |
Archives of virology |
| authorswithroles_txt_mv |
Takenaka, A. @@oth@@ Gibbs, C. J. @@oth@@ Gajdusek, D. C. @@oth@@ |
| publishDateDaySort_date |
1985-03-01T00:00:00Z |
| hierarchy_top_id |
NLEJ18899582X |
| id |
NLEJ208275169 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">NLEJ208275169</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230506160955.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">070528s1985 xx |||||o 00| ||eng c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)NLEJ208275169</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Antiviral neutralizing antibody to Hantaan virus as determined by plaque reduction technique</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">1985</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">10</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Summary The 76–118 strain of Hantaan virus was titrated in E6 (Vero) cells by the plaque method using agarose overlay medium. Visible plaques, formed 10 days post-infection, were uniformly 2–3 mm in diameter. Dose-response experiments showed that a single infectious particle initiated the formation of a plaque. Infectivity titers by the plaque method were equivalent to those obtained by the endpoint method (TCID50) using the immunofluorescence antibody technique (IFA) for antigen detection. The single-cycle growth pattern of the virus showed an eclipse phase of 7 to 9 hours, with production of cell-free infectious virus 18 hours post-infection. Plaque reduction neutralization tests suggested that complement enhanced the neutralizing activity of sera; rat sera were particularly complement-dependent. The plaque reduction neutralization test was about 10 times more sensitive than the TCID50 neutralization test. Convalescent phase sera from patients with hemorrhagic fever with renal syndrome (HFRS) having higher IF antibody titers to Hantaan virus than to nephropathia epidemica (NE) virus were capable of neutralizing Hantaan virus, while sera from patients with higher IF antibody titers to NE virus than Hantaan virus did not contain neutralizing antibody to Hantaan virus.</subfield></datafield><datafield tag="533" ind1=" " ind2=" "><subfield code="f">Springer Online Journal Archives 1860-2002</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Takenaka, A.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gibbs, C. J.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gajdusek, D. C.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">in</subfield><subfield code="t">Archives of virology</subfield><subfield code="d">1939</subfield><subfield code="g">84(1985) vom: März/Apr., Seite 197-206</subfield><subfield code="w">(DE-627)NLEJ18899582X</subfield><subfield code="w">(DE-600)1458460-8</subfield><subfield code="x">1432-8798</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:84</subfield><subfield code="g">year:1985</subfield><subfield code="g">month:03/04</subfield><subfield code="g">pages:197-206</subfield><subfield code="g">extent:10</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://dx.doi.org/10.1007/BF01378972</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-1-SOJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_NL_ARTICLE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">84</subfield><subfield code="j">1985</subfield><subfield code="c">3/4</subfield><subfield code="h">197-206</subfield><subfield code="g">10</subfield></datafield></record></collection>
|
| series2 |
Springer Online Journal Archives 1860-2002 |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)NLEJ18899582X |
| format |
electronic Article |
| delete_txt_mv |
keep |
| collection |
NL |
| remote_str |
true |
| illustrated |
Not Illustrated |
| issn |
1432-8798 |
| topic_title |
Antiviral neutralizing antibody to Hantaan virus as determined by plaque reduction technique |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
a t at c j g cj cjg d c g dc dcg |
| hierarchy_parent_title |
Archives of virology |
| hierarchy_parent_id |
NLEJ18899582X |
| hierarchy_top_title |
Archives of virology |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)NLEJ18899582X (DE-600)1458460-8 |
| title |
Antiviral neutralizing antibody to Hantaan virus as determined by plaque reduction technique |
| spellingShingle |
Antiviral neutralizing antibody to Hantaan virus as determined by plaque reduction technique |
| ctrlnum |
(DE-627)NLEJ208275169 |
| title_full |
Antiviral neutralizing antibody to Hantaan virus as determined by plaque reduction technique |
| journal |
Archives of virology |
| journalStr |
Archives of virology |
| lang_code |
eng |
| isOA_bool |
false |
| recordtype |
marc |
| publishDateSort |
1985 |
| contenttype_str_mv |
zzz |
| container_start_page |
197 |
| container_volume |
84 |
| physical |
10 |
| format_se |
Elektronische Aufsätze |
| title_sort |
antiviral neutralizing antibody to hantaan virus as determined by plaque reduction technique |
| title_auth |
Antiviral neutralizing antibody to Hantaan virus as determined by plaque reduction technique |
| abstract |
Summary The 76–118 strain of Hantaan virus was titrated in E6 (Vero) cells by the plaque method using agarose overlay medium. Visible plaques, formed 10 days post-infection, were uniformly 2–3 mm in diameter. Dose-response experiments showed that a single infectious particle initiated the formation of a plaque. Infectivity titers by the plaque method were equivalent to those obtained by the endpoint method (TCID50) using the immunofluorescence antibody technique (IFA) for antigen detection. The single-cycle growth pattern of the virus showed an eclipse phase of 7 to 9 hours, with production of cell-free infectious virus 18 hours post-infection. Plaque reduction neutralization tests suggested that complement enhanced the neutralizing activity of sera; rat sera were particularly complement-dependent. The plaque reduction neutralization test was about 10 times more sensitive than the TCID50 neutralization test. Convalescent phase sera from patients with hemorrhagic fever with renal syndrome (HFRS) having higher IF antibody titers to Hantaan virus than to nephropathia epidemica (NE) virus were capable of neutralizing Hantaan virus, while sera from patients with higher IF antibody titers to NE virus than Hantaan virus did not contain neutralizing antibody to Hantaan virus. |
| abstractGer |
Summary The 76–118 strain of Hantaan virus was titrated in E6 (Vero) cells by the plaque method using agarose overlay medium. Visible plaques, formed 10 days post-infection, were uniformly 2–3 mm in diameter. Dose-response experiments showed that a single infectious particle initiated the formation of a plaque. Infectivity titers by the plaque method were equivalent to those obtained by the endpoint method (TCID50) using the immunofluorescence antibody technique (IFA) for antigen detection. The single-cycle growth pattern of the virus showed an eclipse phase of 7 to 9 hours, with production of cell-free infectious virus 18 hours post-infection. Plaque reduction neutralization tests suggested that complement enhanced the neutralizing activity of sera; rat sera were particularly complement-dependent. The plaque reduction neutralization test was about 10 times more sensitive than the TCID50 neutralization test. Convalescent phase sera from patients with hemorrhagic fever with renal syndrome (HFRS) having higher IF antibody titers to Hantaan virus than to nephropathia epidemica (NE) virus were capable of neutralizing Hantaan virus, while sera from patients with higher IF antibody titers to NE virus than Hantaan virus did not contain neutralizing antibody to Hantaan virus. |
| abstract_unstemmed |
Summary The 76–118 strain of Hantaan virus was titrated in E6 (Vero) cells by the plaque method using agarose overlay medium. Visible plaques, formed 10 days post-infection, were uniformly 2–3 mm in diameter. Dose-response experiments showed that a single infectious particle initiated the formation of a plaque. Infectivity titers by the plaque method were equivalent to those obtained by the endpoint method (TCID50) using the immunofluorescence antibody technique (IFA) for antigen detection. The single-cycle growth pattern of the virus showed an eclipse phase of 7 to 9 hours, with production of cell-free infectious virus 18 hours post-infection. Plaque reduction neutralization tests suggested that complement enhanced the neutralizing activity of sera; rat sera were particularly complement-dependent. The plaque reduction neutralization test was about 10 times more sensitive than the TCID50 neutralization test. Convalescent phase sera from patients with hemorrhagic fever with renal syndrome (HFRS) having higher IF antibody titers to Hantaan virus than to nephropathia epidemica (NE) virus were capable of neutralizing Hantaan virus, while sera from patients with higher IF antibody titers to NE virus than Hantaan virus did not contain neutralizing antibody to Hantaan virus. |
| collection_details |
GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE |
| title_short |
Antiviral neutralizing antibody to Hantaan virus as determined by plaque reduction technique |
| url |
http://dx.doi.org/10.1007/BF01378972 |
| remote_bool |
true |
| author2 |
Takenaka, A. Gibbs, C. J. Gajdusek, D. C. |
| author2Str |
Takenaka, A. Gibbs, C. J. Gajdusek, D. C. |
| ppnlink |
NLEJ18899582X |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth |
| up_date |
2024-07-06T11:42:23.377Z |
| _version_ |
1803829791558729728 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">NLEJ208275169</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230506160955.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">070528s1985 xx |||||o 00| ||eng c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)NLEJ208275169</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Antiviral neutralizing antibody to Hantaan virus as determined by plaque reduction technique</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">1985</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">10</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Summary The 76–118 strain of Hantaan virus was titrated in E6 (Vero) cells by the plaque method using agarose overlay medium. Visible plaques, formed 10 days post-infection, were uniformly 2–3 mm in diameter. Dose-response experiments showed that a single infectious particle initiated the formation of a plaque. Infectivity titers by the plaque method were equivalent to those obtained by the endpoint method (TCID50) using the immunofluorescence antibody technique (IFA) for antigen detection. The single-cycle growth pattern of the virus showed an eclipse phase of 7 to 9 hours, with production of cell-free infectious virus 18 hours post-infection. Plaque reduction neutralization tests suggested that complement enhanced the neutralizing activity of sera; rat sera were particularly complement-dependent. The plaque reduction neutralization test was about 10 times more sensitive than the TCID50 neutralization test. Convalescent phase sera from patients with hemorrhagic fever with renal syndrome (HFRS) having higher IF antibody titers to Hantaan virus than to nephropathia epidemica (NE) virus were capable of neutralizing Hantaan virus, while sera from patients with higher IF antibody titers to NE virus than Hantaan virus did not contain neutralizing antibody to Hantaan virus.</subfield></datafield><datafield tag="533" ind1=" " ind2=" "><subfield code="f">Springer Online Journal Archives 1860-2002</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Takenaka, A.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gibbs, C. J.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gajdusek, D. C.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">in</subfield><subfield code="t">Archives of virology</subfield><subfield code="d">1939</subfield><subfield code="g">84(1985) vom: März/Apr., Seite 197-206</subfield><subfield code="w">(DE-627)NLEJ18899582X</subfield><subfield code="w">(DE-600)1458460-8</subfield><subfield code="x">1432-8798</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:84</subfield><subfield code="g">year:1985</subfield><subfield code="g">month:03/04</subfield><subfield code="g">pages:197-206</subfield><subfield code="g">extent:10</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://dx.doi.org/10.1007/BF01378972</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-1-SOJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_NL_ARTICLE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">84</subfield><subfield code="j">1985</subfield><subfield code="c">3/4</subfield><subfield code="h">197-206</subfield><subfield code="g">10</subfield></datafield></record></collection>
|
| score |
7.4027834 |